Research Paper

Karlsberg Schaffer, S.

Research Paper
February 2013

Forecasters predict that the population of people aged 65+ in the UK will double by 2050, constituting a quarter of the total population. This will seriously challenge the NHS and the social care system. The ageing population is expensive: average NHS spending on 65+ households is nearly double that on households under 65 years of age. Formal care provided by the state, however, is not the only resource on which the elderly rely. England alone has nearly six million informal carers.

Shah, K. and Devlin, N.

Research Paper
December 2012

The UK Government is proposing to include "burden of illness" criteria in its scheme for value based pricing of branded medicines, potentially according higher rewards to medicines that treat more burdensome diseases. The 2010 Consultation Document includes a definition of burden of illness that incorporates both severity (length or quality of life) and "unmet need" (whether and what treatment exists). Little empirical evidence is available, however, on societal attitudes towards these definitions.

Shah, K., Tsuchiya, A., Risa Hole, A. and Wailoo, A.

Research Paper
December 2012

In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that extend life at the end of life.  This includes an option for approving such treatments for use in the NHS if certain criteria are met, even if base case cost-effectiveness estimates exceed the range usually considered acceptable.

Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D.

Research Paper
April 2012

Diagnostics not only facilitate health gain and cost savings, but also provide information to inform patients’ decisions on interventions and to clarify how their behaviour may affect their health. Current pricing and reimbursement systems for diagnostics, however, are not efficient and provide poor incentives for new diagnostic approaches.  Prices often are driven by administrative practice and expected production cost, rather than assessments of value.

Feng, Y., May, A., Farrar, S. and Sutton, M.

Research Paper
April 2012

In April 2006, payment thresholds were raised for GPs who participate in Scotland’s Ouality and Outcomes Framework.  GPs were required to meet new, higher thresholds on some indicators to receive maximum levels of payment.  In this paper, OHE’s Yan Feng and her colleagues examine whether this change in fact improved GP performance and whether the impact differed across GPs. Specifically, they examine whether low-, mid- and high-performing GPs changed behaviour and, if so, to what extent.

Feng, Y., Parkin, D. and Devlin, N.

Research Paper
April 2012

The NHS Patient Reported Outcome Measures (PROMs) programme, introduced in April 2009, is a significant development in the routine collection and use of patient reported outcome data.  Data currently are collected for patients both before and after surgery for four elective surgical procedures in the NHS, with plans to expand the practice.

Shah, K., Tsuchiya, A. and Wailoo, A.

Research Paper
December 2011

In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that extend life at the end of life.  This includes an option for approving such treatments for use in the NHS if certain criteria are met, even if base case cost-effectiveness estimates exceed the range usually considered acceptable.

 

Feng, Y., Farrar, S., Sutton, M. and May, A.

Research Paper
November 2011

This paper investigates how the increased rate of Quality and Outcomes Framework (QOF) payments implemented on 1 April 2005 affects Scottish general practitioners’ (GPs) intrinsic, extrinsic and overall motivation. A first difference method is used to model GPs’ intrinsic and overall motivation. The main finding is that the increased QOF payment effectively motivated GPs' health care supply, but it also 'crowded out' GPs' intrinsic motivation.

Sussex, J., Towse, A. and Devlin, N.

Research Paper
August 2011

Recent reforms to the National Health Service (NHS) in England include important changes in the regulation of prices for new medicines. From January 2014, the existing Pharmaceutical Pricing Regulation Scheme (PPRS) will be replaced by “value based pricing” (VBP) for branded medicines sold to the NHS. This will apply only to new medicines; those marketed before 2014 will continue to be governed by the PPRS.

Shah, K., Sussex, J., Hernandez-Villafuerte, K. and Garau, M., Rotolo, D., Hopkins, M.M., Grassano, N., Crane, P., Lang, F., Hutton, J., Pateman, C., Mawer, A., Farrell, C. and Sharp, T.

Research Paper
July 2014

As earlier OHE research has demonstrated, sources of funding for medical research—public, charity and private sector—are complementary, not duplicative. The three sectors also differ in their approaches. As a result, decreased funding from one would not only reduce the overall financing available, but also change the nature of the research effort overall. This is a concern given that austerity in government spending in the UK is likely to continue for some time. This report produced by OHE and SPRU at the University of Sussex for Cancer Research UK explores two sets of questions: 1.

Pages

Subscribe to RSS - Research Paper